You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 7, April 10, 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (83)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Unresolved Issues in the Role of Cyclooxygenase-2 in Normal Physiologic Processes and Disease

Peter E. Lipsky, MD; Peter Brooks, MD; Leslie J. Crofford, MD; Raymond DuBois, MD, PhD; David Graham, MD; Lee S. Simon, MD; Leo B. A. van de Putte, MD, PhD, FRCP; Steven B. Abramson, MD

Arch Intern Med. 2000;160:913-920.

Originally suggested to function mainly in inflammatory situations, recent data have implied important roles for the cyclooxygenase-2 isoenzyme in reproductive biologic processes, renal and neurologic function, and the antithrombotic activities of endothelial cells. As cyclooxygenase-2–specific inhibitors have recently become available as analgesic and anti-inflammatory drugs, a comprehensive view of this rapidly evolving field is necessary to anticipate both the potential therapeutic benefits and toxic effects associated with these agents.


From the University of Texas Southwestern Medical Center, Dallas (Dr Lipsky); The University of Queensland, Brisbane, Australia (Dr Brooks); University of Michigan Medical Center, Ann Arbor (Dr Crofford); Vanderbilt University Medical Center, Nashville, Tenn (Dr DuBois); Veterans Affairs Medical Center Houston, Houston, Tex (Dr Graham); Harvard Medical School, Boston, Mass (Dr Simon); University Hospital Nijmegen, Nijmegen, the Netherlands (Dr van de Putte); and New York University School of Medicine, New York, NY (Dr Abramson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(7):1046-1047.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cyclooxygenases: structural and functional insights
Rouzer and Marnett
J. Lipid Res. 2009;50:S29-S34.
ABSTRACT | FULL TEXT  

Selective and Nonselective Cyclooxygenase-2 Inhibitors and Experimental Fracture-Healing. Reversibility of Effects After Short-Term Treatment
Gerstenfeld et al.
JBJS 2007;89:114-125.
ABSTRACT | FULL TEXT  

Etoricoxib: A Highly Selective COX-2 Inhibitor
Martina et al.
The Annals of Pharmacotherapy 2005;39:854-862.
ABSTRACT | FULL TEXT  

Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children
Turner and Ford
EDUCATION AND PRACTICE 2004;89:ep46-ep49.
FULL TEXT  

Phospholipase D Isozymes Mediate Epigallocatechin Gallate-induced Cyclooxygenase-2 Expression in Astrocyte Cells
Kim et al.
J. Biol. Chem. 2004;279:38125-38133.
ABSTRACT | FULL TEXT  

Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
Solomon et al.
Circulation 2004;109:2068-2073.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Inhibitors
Gajraj
Anesth. Analg. 2003;96:1720-1738.
FULL TEXT  

Tackling ischaemic heart disease in rheumatoid arthritis
Kitas and Erb
Rheumatology (Oxford) 2003;42:607-613.
FULL TEXT  

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning
Bolli et al.
Cardiovasc Res 2002;55:506-519.
ABSTRACT | FULL TEXT  

The Cyclooxygenase Inhibitors Indomethacin and Rofecoxib Reduce Regional Cerebral Blood Flow Evoked by Somatosensory Stimulation in Rats
Bakalova et al.
Exp. Biol. Med. 2002;227:465-473.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Blockade Does Not Impair Endothelial Vasodilator Function in Healthy Volunteers: Randomized Evaluation of Rofecoxib Versus Naproxen on Endothelium-Dependent Vasodilatation
Verma et al.
Circulation 2001;104:2879-2882.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Gene Expression and Regulation in Human Retinal Pigment Epithelial Cells
Chin et al.
IOVS 2001;42:2338-2346.
ABSTRACT | FULL TEXT  

Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer
Paterson and Lawrence
QJM 2001;94:445-448.
ABSTRACT | FULL TEXT  

Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors
Cruz-Fernandez
Eur Heart J Suppl 2001;3:I23-I30.
ABSTRACT  

Celecoxib- and Rofecoxib-Induced Delirium
MACKNIGHT and ROJAS-FERNANDEZ
J. Neuropsychiatry Clin. Neurosi. 2001;13:305-306.
FULL TEXT  

Are COX-2 Inhibitors as Effective as Conventional NSAIDs in Acute Pain States?
Bannwarth and Lipsky
Arch Intern Med 2001;161:127-128.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.